Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2023-03-10 | 2022-11-03 |
| Drug Identification Number | 02499916 | 02499916 |
| Brand name | LEVOTHYROXINE SODIUM INJECTION | LEVOTHYROXINE SODIUM INJECTION |
| Common or Proper name | LEVOTHYROXINE SODIUM INJECTION | LEVOTHYROXINE SODIUM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM |
| Strength(s) | 40MCG | 40MCG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 5 mL | 5 mL |
| ATC code | H03AA | H03AA |
| ATC description | THYROID PREPARATIONS | THYROID PREPARATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-12-31 | 2022-12-31 |
| Actual start date | 2022-12-31 | 2022-12-31 |
| Estimated end date | 2023-03-08 | 2023-02-15 |
| Actual end date | 2023-03-08 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 40 mcg/mL SD Vial 5 mL and 100 mcg/mL SD Vial 5 mL effective December 31, 2022 until March 8, 2023. Please note all current inventory of these products is currently short-dated and expires December 31, 2022. | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 40 mcg/mL SD Vial 5 mL and 100 mcg/mL SD Vial 5 mL effective December 31, 2022 until February 15, 2023. Please note all current inventory of these products is currently short-dated and expires December 31, 2022. |
| Health Canada comments |